TER-2013

Terremoto Biosciences Inc. · Phase 1 active Small molecule

At a glance

Generic name	TER-2013
Sponsor	Terremoto Biosciences Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TER-2013 CI brief — competitive landscape report
TER-2013 updates RSS · CI watch RSS
Terremoto Biosciences Inc. portfolio CI